Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracil
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Adenocarcinoma
Conditions
Adenocarcinoma
Trial Timeline
Sep 1, 2007 → Nov 1, 2013
NCT ID
NCT00548548About Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracil
Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracil is a phase 3 stage product being developed by Chugai Pharmaceutical for Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00548548. Target conditions include Adenocarcinoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00548548 | Phase 3 | Completed |
Competing Products
20 competing products in Adenocarcinoma